|Bid||0.2507 x 200000|
|Ask||0.2604 x 200000|
|Day's Range||0.2550 - 0.2550|
|52 Week Range||0.2247 - 1.1500|
|Beta (3Y Monthly)||0.44|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs May 23.) ArQule, Inc. (NASDAQ: ARQL ) Turning Point ...
On a per-share basis, the San Diego-based company said it had a loss of 6 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Organovo (ONVO) delivered earnings and revenue surprises of 37.50% and 4.43%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Diego-based company said it had a loss of 5 cents. The development-stage company focused on commercializing functional human tissue for drug and biological research posted ...
On Thursday, Nov. 8, Organovo Holdings (NYSE: ONVO ) will release its latest earnings report. Check out Benzinga's report to understand the earnings report's implications. Earnings and Revenue Wall Street ...
The direct benefit for Organovo Holdings Inc (NASDAQ:ONVO), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-offRead More...